Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Fumaric Acid Tegeline Injection, marking a significant step in the development of China's first independently developed Class 1 opioid analgesic [1] Group 1: Product Development - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist [1] - The product is expected to be launched in China in January 2024 [1] - The company has invested approximately 200 million yuan in the research and development of this project [1] Group 2: Market Context - Oliceridine, a similar product developed by Trevena, was approved for sale in the United States in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023 [1] - No sales data for Oliceridine in China has been reported as of now [1]